U.S. markets closed
  • S&P 500

    3,845.08
    +13.69 (+0.36%)
     
  • Dow 30

    31,037.68
    +69.86 (+0.23%)
     
  • Nasdaq

    11,361.85
    +39.61 (+0.35%)
     
  • Russell 2000

    1,727.55
    -13.78 (-0.79%)
     
  • Crude Oil

    98.28
    -0.25 (-0.25%)
     
  • Gold

    1,737.30
    +0.80 (+0.05%)
     
  • Silver

    19.09
    +0.01 (+0.05%)
     
  • EUR/USD

    1.0188
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    2.9130
    +0.1040 (+3.70%)
     
  • GBP/USD

    1.1923
    +0.0001 (+0.01%)
     
  • USD/JPY

    136.0260
    +0.1110 (+0.08%)
     
  • BTC-USD

    20,563.13
    +283.51 (+1.40%)
     
  • CMC Crypto 200

    440.40
    +4.88 (+1.12%)
     
  • FTSE 100

    7,107.77
    +82.30 (+1.17%)
     
  • Nikkei 225

    26,107.65
    -315.82 (-1.20%)
     

Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate Update

  • Oops!
    Something went wrong.
    Please try again later.
·10 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Altimmune, Inc
Altimmune, Inc

Multiple clinical trial data readouts expected in Q3 and Q4 2022

GAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended March 31, 2022 and provided a corporate update.

“We continue to advance the development of pemvidutide, our GLP-1/Glucagon dual receptor agonist and look forward to reporting both weight loss and liver fat reduction data from multiple ongoing clinical trials later this year,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “Based on a greater than 10% weight loss after only 12 weeks of treatment, we believe that pemvidutide has the potential to deliver weight loss comparable to the results of bariatric surgery in people with obesity. In addition, we believe that pemvidutide will have a highly differentiated product profile compared to other products in development—no dose titration, faster weight loss, and robust reductions in lipids. If achieved, we believe these features would translate into greater ease of administration, improved adherence to therapy, and greater potential for cardiovascular benefit.”

Recent Highlights and Anticipated Milestones:

Pemvidutide1 (ALT-801)

  • Enrollment ongoing in 48-week Phase 2 MOMENTUM trial of pemvidutide in obesity

    • This Phase 2 trial is being conducted at approximately 25 sites in the U.S., with Dr. Lou Aronne, Professor of Clinical Medicine, Weill Cornell Medical College, a leading authority in obesity and obesity clinical trials, serving as the Principal Investigator.

    • The trial is expected to enroll approximately 320 non-diabetic subjects with either obesity or overweight. Subjects are being randomized 1:1:1:1 to 1.2 mg, 1.8 mg, 2.4 mg pemvidutide or placebo administered weekly for 48 weeks.

    • The primary endpoint is the relative (percent) change in body weight at 48 weeks compared to baseline, with additional readouts including metabolic and lipid profiles, cardiovascular measures and glucose homeostasis.

    • Dosing has commenced and an interim analysis is planned to assess changes in body weight after 24 weeks of treatment, with an expected readout in Q4 2022.

  • Enrollment completed in 12-week Phase 1b nonalcoholic fatty liver disease (NAFLD) trial

    • This Phase 1b trial is being conducted in the U.S., with Dr. Stephen A. Harrison, Director, Pinnacle Research and University of Oxford, serving as Principal Investigator.

    • The trial is comprised of non-diabetic and diabetic subjects randomized 1:1:1:1 to 1.2 mg, 1.8 mg, 2.4 mg pemvidutide or placebo administered weekly for 12 weeks.

    • The primary efficacy readouts are liver fat reduction and weight loss at day 85 (12 weeks).

    • Data readout expected in Q3 2022.

  • Enrollment ongoing in Phase 1b NAFLD extension trial

    • This 12-week extension trial allows subjects who have completed the 12-week Phase 1b NAFLD trial to receive a total of 24 weeks of treatment, with an expected data readout on weight loss at 24 weeks in Q4 2022.

  • Enrollment ongoing in Phase 1b trial of diabetic subjects with obesity and overweight

    • This 12-week trial will expand on findings from our first-in-human trial in subjects with obesity and overweight, in whom decreased insulin resistance and maintenance of glucose control were observed, including subjects with pre-diabetes.

1 proposed INN

Upcoming presentations summarizing data from the Phase 1 trial of pemvidutide at international Scientific Meetings

  • May 27, 2022: Global NASH Congress, London UK –The Emerging Weight Loss Therapeutics and Implications for the NASH Treatment Paradigm. Oral presentation by Scott Harris, M.D., Chief Medical Officer, Altimmune.

  • June 6, 2022: American Diabetes Association (ADA) Scientific Sessions, New Orleans, LA –Pemvidutide (ALT-801), a Balanced (1:1) GLP-1/Glucagon Dual Receptor Agonist, Induces Rapid and Marked Weight Loss without the Need for Dose Titration in People with Overweight/Obesity. Oral presentation by Samuel Klein, M.D., William H. Danforth Professor of Medicine and Nutritional Science, Washington University School of Medicine.

  • June 25, 2022: EASL International Liver Congress, London, UK –Pemvidutide (ALT-801), a novel GLP-1/glucagon dual receptor agonist, induces significant reductions in major lipid classes implicated in the pathogenesis of NASH and other conditions. Oral presentation by Stephen Harrison, M.D. Medical Director, Pinnacle Research and University of Oxford.

HepTcell

  • Enrollment continuing in the Phase 2 clinical trial in chronic hepatitis B, with data readout expected H1 2023

    • Readouts are expected to include virological markers of hepatitis B infection and functional cure.

Financial Results for the Three Months Ended March 31, 2022

  • Altimmune had cash, cash equivalents and restricted cash totaling $180.0 million at March 31, 2022.

  • Revenue was minimal for the three months ended March 31, 2022 compared to $0.8 million in the same period in 2021. The change in revenue quarter over quarter was primarily due to the discontinuation of development activities for the T-COVID and NasoShield programs.

  • Research and development expenses were $15.1 million for the three months ended March 31, 2022, compared to $11.9 million in the same period in 2021. The expenses for the quarter ended March 31, 2022 included $10.8 million in direct costs related to development activities for pemvidutide and $2.5 million in direct costs related to development activities for HepTcell.

  • General and administrative expenses were $4.4 million for the three months ended March 31, 2022, compared to $3.8 million in the same period in 2021. The change was primarily attributable to increased stock compensation expense.

  • Net loss for the three months ended March 31, 2022 was $19.4 million, or $0.44 net loss per share, compared to $14.9 million in the same period in 2021, or $0.38 net loss per share.

  • 2022 operating expense guidance will be provided on the conference call.

Conference Call Information:

Date:

Thursday, May 12

Time:

8:30 am Eastern Time

Domestic Dial-in:

(800) 225-9448

International Dial-in:

(203) 518-9708

Conference ID:

ALTQ122

Webcast:

https://edge.media-server.com/mmc/p/j5i9f735

Following the conclusion of the call, the webcast will be available for replay on the Investor Relations page of the Company’s website at www.altimmune.com. The Company has used, and intends to continue to use, the IR portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

About Pemvidutide

Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. By combining GLP-1 and glucagon activity in a single peptide, pemvidutide has the potential to achieve weight loss comparable to the results of bariatric surgery. Pemvidutide incorporates the EuPortTM domain, a proprietary technology that increases its serum half-life for weekly dosing while slowing the entry of pemvidutide into the bloodstream, which may improve its tolerability. In a 12-week Phase 1 clinical trial, pemvidutide-treated subjects demonstrated striking reductions in body weight, liver fat and serum lipids commonly associated with cardiovascular disease.

About HepTcell

HepTcell is a novel, investigational, immunotherapeutic comprised of nine synthetic peptides representing conserved hepatitis B (HBV) sequences formulated with IC31®, a TLR9-based adjuvant from Valneva SE. The HBV-directed peptides are designed to drive T cell responses against all HBV genotypes towards a functional cure for chronic HBV in patients of diverse genetic backgrounds.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Forward-Looking Statement

Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the timing of key milestones for our clinical assets, the timing of the data readouts of the NAFLD trials, drug-drug interaction trial, and the Phase 2 obesity clinical trial of pemvidutide, the timing of the data readouts for the Phase 2 clinical trial of HepTcell, and the prospects for regulatory approval, commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Altimmune, Inc. (the “Company”) may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including risks relating to: potential impacts from the ongoing conflict in Ukraine and the COVID-19 pandemic, such as delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy; the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company’s product candidates; the Company’s ability to manufacture clinical trial materials on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company’s filings with the U.S. Securities and Exchange Commission, including under the heading “Risk Factors” in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2021 and our other filings with the SEC, which are available at www.sec.gov.

Investor & Media Contacts:

Rich Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com

ALTIMMUNE, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)

March 31,

December 31,

2022

2021

(unaudited)

ASSETS

Current assets:

Cash and cash equivalents

$

179,947

$

190,301

Restricted cash

34

34

Total cash, cash equivalents and restricted cash

179,981

190,335

Accounts receivable

193

429

Income tax and R&D incentive receivables

5,880

5,410

Prepaid expenses and other current assets

5,039

7,952

Total current assets

191,093

204,126

Property and equipment, net

1,337

1,448

Intangible assets, net

12,419

12,419

Other assets

811

872

Total assets

$

205,660

$

218,865

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$

2,205

$

2,034

Contingent consideration

4,310

6,090

Accrued expenses and other current liabilities

12,609

10,152

Total current liabilities

19,124

18,276

Other long-term liabilities

1,668

1,454

Total liabilities

20,792

19,730

Commitments and contingencies (Note 16)

Stockholders’ equity:

Common stock, $0.0001 par value; 200,000,000 shares authorized; 43,219,896 and 40,993,768 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively

4

4

Additional paid-in capital

502,505

497,342

Accumulated deficit

(312,601

)

(293,171

)

Accumulated other comprehensive loss, net

(5,040

)

(5,040

)

Total stockholders’ equity

184,868

199,135

Total liabilities and stockholders’ equity

$

205,660

$

218,865

ALTIMMUNE, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(unaudited)
(in thousands, except share and per share data)

For the Three Months Ended

March 31,

2022

2021

Revenues

$

32

$

838

Operating expenses:

Research and development

15,104

11,878

General and administrative

4,427

3,821

Total operating expenses

19,531

15,699

Loss from operations

(19,499

)

(14,861

)

Other income (expense):

Interest expense

(62

)

(12

)

Interest income

21

42

Other income (expense), net

110

(33

)

Total other income (expense), net

69

(3

)

Net loss

(19,430

)

(14,864

)

Other comprehensive income — unrealized gain on short-term investments

5

Comprehensive loss

$

(19,430

)

$

(14,859

)

Net loss per share, basic and diluted

$

(0.44

)

$

(0.38

)

Weighted-average common shares outstanding, basic and diluted

43,969,481

38,914,990